amantadine has been researched along with Basal Ganglia Diseases in 38 studies
amant: an antiviral compound consisting of an adamantane derivative chemically linked to a water-solube polyanioic matrix; structure in first source
Basal Ganglia Diseases: Diseases of the BASAL GANGLIA including the PUTAMEN; GLOBUS PALLIDUS; claustrum; AMYGDALA; and CAUDATE NUCLEUS. DYSKINESIAS (most notably involuntary movements and alterations of the rate of movement) represent the primary clinical manifestations of these disorders. Common etiologies include CEREBROVASCULAR DISORDERS; NEURODEGENERATIVE DISEASES; and CRANIOCEREBRAL TRAUMA.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In more than 50 percent of the cases of initial tremor induced by lithium therapy, oxprenolol in daily doses of 160--240 mg produced good effects and moderate improvement was noted in a few further cases." | 9.04 | Therapy of extrapyramidal side effects, with particular reference to persistent dyskinesia and lithium tremor. ( Pöldinger, W, 1978) |
| "Amantadine was given to 11 psychotic patients, concurrently on neuroleptic medications, who required treatment of neuroleptic-induced extrapyramidal side effects." | 5.26 | The effect of amantadine on prolactin levels and galactorrhea on neuroleptic-treated patients. ( Siever, LJ, 1981) |
| " In more than 50 percent of the cases of initial tremor induced by lithium therapy, oxprenolol in daily doses of 160--240 mg produced good effects and moderate improvement was noted in a few further cases." | 5.04 | Therapy of extrapyramidal side effects, with particular reference to persistent dyskinesia and lithium tremor. ( Pöldinger, W, 1978) |
| "Amantadine was found to be comparable in effect to benztropine mesylate, but with fewer side effects." | 2.64 | A controlled trial of amantadine in drug-induced extrapyramidal disorders. ( Bernardo, DL; DiMascio, A; Greenblatt, DJ; Marder, JE, 1976) |
| "Our patient had developed overt parkinsonism presenting with a resting tremor, expressionless face, and lack of blinking along with marked cogwheel rigidity and a stooped, slow gait." | 2.43 | Extrapyramidal parkinsonism complicating acute organophosphate insecticide poisoning. ( Bar-Joseph, G; Bentur, Y; Cahana, A; Hershman, E; Shahar, E, 2005) |
| "Once a parkinsonian syndrome was diagnosed, she was given amantadine therapy with complete recovery." | 1.31 | Extra-pyramidal parkinsonism complicating organophosphate insecticide poisoning. ( Andraws, J; Shahar, E, 2001) |
| "Amantadine was given to 11 psychotic patients, concurrently on neuroleptic medications, who required treatment of neuroleptic-induced extrapyramidal side effects." | 1.26 | The effect of amantadine on prolactin levels and galactorrhea on neuroleptic-treated patients. ( Siever, LJ, 1981) |
| " In the antipsychotic classification, special attention is given to side effects (extrapyramidal motor signs, tardive dyskinesias, akathisis) and to dosage for the elderly." | 1.25 | Observations on the psychopharmacology of the aged. ( Eisdorfer, C, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 33 (86.84) | 18.7374 |
| 1990's | 2 (5.26) | 18.2507 |
| 2000's | 3 (7.89) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Shahar, E | 2 |
| Bentur, Y | 1 |
| Bar-Joseph, G | 1 |
| Cahana, A | 1 |
| Hershman, E | 1 |
| Rojtman, M | 1 |
| Apter, E | 1 |
| Lahav, S | 1 |
| Tiano, S | 1 |
| Siever, LJ | 1 |
| Borison, RL | 1 |
| Neppe, VM | 1 |
| Allen, RM | 1 |
| Gangadhar, BN | 1 |
| Desai, NG | 1 |
| Channabasavanna, SM | 1 |
| Gómez, EA | 1 |
| Abrams, AA | 1 |
| Braff, DL | 1 |
| Silver, H | 1 |
| Geraisy, N | 1 |
| Yasuoka, T | 1 |
| Ikeda, M | 1 |
| Maki, N | 1 |
| Hokoishi, K | 1 |
| Komori, K | 1 |
| Tanabe, H | 1 |
| Andraws, J | 1 |
| DiMascio, A | 2 |
| Bernardo, DL | 2 |
| Greenblatt, DJ | 2 |
| Marder, JE | 2 |
| Mindham, RH | 2 |
| Pöldinger, W | 1 |
| Eisdorfer, C | 1 |
| Ananth, J | 1 |
| Sangani, H | 1 |
| Noonan, JP | 1 |
| Agnoli, A | 1 |
| Ruggieri, S | 1 |
| Casacchia, M | 1 |
| Schubert, U | 1 |
| Fischer, GJ | 1 |
| Glass, J | 1 |
| Messiha, FS | 1 |
| Keepers, GA | 1 |
| Casey, DE | 1 |
| Nestelbaum, Z | 1 |
| Siris, SG | 1 |
| Rifkin, A | 1 |
| Klar, H | 1 |
| Reardon, GT | 1 |
| McEvoy, JP | 1 |
| Hitri, A | 1 |
| Craft, RB | 1 |
| Sethi, R | 1 |
| Sinha, D | 1 |
| Mundinger, F | 1 |
| Milios, E | 1 |
| Guzé, BH | 1 |
| Baxter, LR | 1 |
| Lazarus, A | 1 |
| Rosse, R | 1 |
| Ciolino, C | 1 |
| Soyka, D | 1 |
| Merrick, EM | 1 |
| Schmitt, PP | 1 |
| Parkes, D | 1 |
| Brogden, RN | 1 |
| Speight, TM | 1 |
| Avery, GS | 1 |
| Calne, DB | 1 |
| Reid, JL | 1 |
| Boczán, G | 1 |
| Ferrari, P | 1 |
| Robotti, E | 1 |
| Nardini, M | 1 |
| Gaind, R | 1 |
| Anstee, BH | 1 |
| Rimmer, L | 1 |
| Dencker, SJ | 1 |
| Lindberg, D | 1 |
| Malm, U | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Utility of Amantadine Hydrochloride in the Treatment of Post-traumatic Irritability: A Randomized, Double-Blind, Placebo-Controlled Trial[NCT00627250] | 76 participants (Actual) | Interventional | 2003-03-31 | Completed | |||
| Combining a Dopamine Agonist and Selective Serotonin Reuptake Inhibitor for Treatment of Depression: A Double-Blind, Randomized Study[NCT00086307] | Phase 2 | 39 participants (Actual) | Interventional | 2004-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The Montgomery Asberg Depression Rating Scale (MADRS) is a 10 item scale for assessing the severity of depression. Items are rated on a scale of 0 to 6, so the maximum score is 60 and the minimum is 0, where 60 is the most severe depression. Scores of 18 or greater are generally considered to indicate a moderate level of depression. (NCT00086307)
Timeframe: Weekly
| Intervention | Score on a scale (Least Squares Mean) |
|---|---|
| Pramipexole | 22.629 |
| Escitalopram | 26.102 |
| Escitalopram and Pramipexole | 29.455 |
7 reviews available for amantadine and Basal Ganglia Diseases
| Article | Year |
|---|---|
Extrapyramidal parkinsonism complicating acute organophosphate insecticide poisoning.
Topics: Acute Disease; Adolescent; Amantadine; Antiparkinson Agents; Basal Ganglia Diseases; Dimethoate; Hum | 2005 |
Role of amantadine in the management of neuroleptic-induced extrapyramidal syndromes: overview and pharmacology.
Topics: Amantadine; Animals; Antipsychotic Agents; Apomorphine; Basal Ganglia Diseases; Binding, Competitive | 1983 |
Clinical management of acute neuroleptic-induced extrapyramidal syndromes.
Topics: Acute Disease; Adolescent; Adult; Age Factors; Akathisia, Drug-Induced; Amantadine; Antipsychotic Ag | 1986 |
Current concepts. Neuroleptic malignant syndrome.
Topics: Amantadine; Basal Ganglia Diseases; Bromocriptine; Catatonia; Dantrolene; Diagnosis, Differential; D | 1985 |
Amantadine.
Topics: Acetylcholine; Amantadine; Animals; Antiviral Agents; Basal Ganglia Diseases; Behavior, Animal; Cate | 1974 |
Levodopa: a review of its pharmacological properties and therapeutic use with particular reference to Parkinsonism.
Topics: Amantadine; Animals; Aromatic Amino Acid Decarboxylase Inhibitors; Basal Ganglia Diseases; Brain Che | 1971 |
Antiparkinsonian drugs: pharmacological and therapeutic aspects.
Topics: Acetylcholine; Adrenergic beta-Antagonists; Amantadine; Amphetamine; Antiparkinson Agents; Apomorphi | 1972 |
12 trials available for amantadine and Basal Ganglia Diseases
| Article | Year |
|---|---|
No difference in the effect of biperiden and amantadine on negative symptoms in medicated chronic schizophrenic patients.
Topics: Adult; Amantadine; Basal Ganglia Diseases; Biperiden; Chronic Disease; Cross-Over Studies; Dopamine | 1995 |
A controlled trial of amantadine in drug-induced extrapyramidal disorders.
Topics: Amantadine; Antipsychotic Agents; Basal Ganglia Diseases; Benztropine; Clinical Trials as Topic; Dru | 1976 |
Assessment of drugs in schizophrenia. Asessment of drug-induced extrapyramidal reactions and of drugs given for their control.
Topics: Amantadine; Antiparkinson Agents; Antipsychotic Agents; Basal Ganglia Diseases; Clinical Trials as T | 1976 |
A controlled trial of amantadine in drug-induced extrapyramidal disorders.
Topics: Amantadine; Antipsychotic Agents; Basal Ganglia Diseases; Benztropine; Clinical Trials as Topic; Dou | 1977 |
Therapy of extrapyramidal side effects, with particular reference to persistent dyskinesia and lithium tremor.
Topics: Adolescent; Adult; Amantadine; Antipsychotic Agents; Basal Ganglia Diseases; Bromocriptine; Chronic | 1978 |
Amantadine in drug-induced extrapyramidal signs: a comparative study.
Topics: Adult; Aged; Amantadine; Basal Ganglia Diseases; Benztropine; Clinical Trials as Topic; Female; Huma | 1975 |
Restatement and prospectives of ergot alkaloids in clinical neurology and psychiatry.
Topics: Aged; Amantadine; Basal Ganglia Diseases; Bromocriptine; Chorea; Clinical Trials as Topic; Depressio | 1978 |
[Treatment of Parkinsonian syndrome using amantadine hydrochloride].
Topics: Adult; Aged; Amantadine; Basal Ganglia Diseases; Clinical Trials as Topic; Drug Evaluation; Electrom | 1975 |
A double-blind crossover comparison of antiparkinson drug therapy: amantadine versus anticholinergics in 90 normal volunteers, with an emphasis on differential effects on memory function.
Topics: Adult; Age Factors; Aged; Amantadine; Antipsychotic Agents; Basal Ganglia Diseases; Benztropine; Cli | 1987 |
A controlled study of the clinical effects of amantadine hydrochloride (Symmetrel).
Topics: Adult; Amantadine; Basal Ganglia Diseases; Benztropine; Clinical Trials as Topic; Female; Humans; Ma | 1973 |
[Experimental design of a pilot study on amantadine in the extrapyramidal syndrome induced by neuroleptic drugs].
Topics: Amantadine; Analysis of Variance; Basal Ganglia Diseases; Clinical Trials as Topic; Evaluation Studi | 1972 |
Comparison of amantadine, orphenadrine, and placebo in the control of phenothiazine-induced Parkinsonism.
Topics: Affect; Amantadine; Basal Ganglia Diseases; Clinical Trials as Topic; Evaluation Studies as Topic; F | 1972 |
19 other studies available for amantadine and Basal Ganglia Diseases
| Article | Year |
|---|---|
[Amantadine in malignant neuroleptic syndrome].
Topics: Amantadine; Antipsychotic Agents; Basal Ganglia Diseases; Humans; Male; Syndrome | 1981 |
The effect of amantadine on prolactin levels and galactorrhea on neuroleptic-treated patients.
Topics: Adolescent; Adult; Amantadine; Antipsychotic Agents; Basal Ganglia Diseases; Female; Galactorrhea; H | 1981 |
Amantadine in the management of extrapyramidal side effects.
Topics: Amantadine; Antipsychotic Agents; Basal Ganglia Diseases; Dyskinesia, Drug-Induced; Dystonia; Humans | 1983 |
The neuroleptic malignant syndrome. A priority system.
Topics: Amantadine; Antipsychotic Agents; Basal Ganglia Diseases; Bromocriptine; Consciousness Disorders; Da | 1984 |
Amantadine in the neuroleptic malignant syndrome.
Topics: Adult; Amantadine; Basal Ganglia Diseases; Haloperidol; Humans; Male; Neuroleptic Malignant Syndrome | 1984 |
[Extrapyramidal reactions and neuroleptic malignant syndrome].
Topics: Adult; Amantadine; Basal Ganglia Diseases; Dantrolene; Haloperidol; Humans; Male; Neuroleptic Malign | 1984 |
Lithium induced cogwheel rigidity: treatment with amantadine.
Topics: Adult; Amantadine; Basal Ganglia Diseases; Bipolar Disorder; Female; Humans; Lithium | 1980 |
[A case of corticobasal degeneration of which movemental disturbances were improved by administration of amantadine].
Topics: Amantadine; Antiparkinson Agents; Apraxias; Basal Ganglia Diseases; Cerebral Cortex; Female; Humans; | 2001 |
Extra-pyramidal parkinsonism complicating organophosphate insecticide poisoning.
Topics: Adolescent; Amantadine; Antiparkinson Agents; Basal Ganglia Diseases; Female; Humans; Insecticides; | 2001 |
Observations on the psychopharmacology of the aged.
Topics: Aged; Amantadine; Antidepressive Agents; Antipsychotic Agents; Basal Ganglia Diseases; Butyrophenone | 1975 |
Neurotoxicity of chlorpromazine and modulation by amantadine as a function of mouse strain.
Topics: Amantadine; Animals; Basal Ganglia Diseases; Chlorpromazine; Male; Mice; Mice, Inbred BALB C; Mice, | 1991 |
Exacerbation of schizophrenia associated with amantadine.
Topics: Acute Disease; Adult; Amantadine; Antipsychotic Agents; Basal Ganglia Diseases; Drug Therapy, Combin | 1986 |
Drug levels and antiparkinsonian drugs in neuroleptic-treated schizophrenic patients.
Topics: Adult; Amantadine; Antiparkinson Agents; Antipsychotic Agents; Basal Ganglia Diseases; Benztropine; | 1987 |
[Experiences with memantine in the treatment of severe spastic and extrapyramidal movement disorders in combination with stereotaxic surgery].
Topics: Adolescent; Adult; Aged; Amantadine; Athetosis; Basal Ganglia Diseases; Cerebral Palsy; Child; Chore | 1985 |
Neuroleptic malignant syndrome and amantadine withdrawal.
Topics: Acute Disease; Amantadine; Basal Ganglia Diseases; Female; Humans; Middle Aged; Neuroleptic Malignan | 1985 |
Dopamine agonists and neuroleptic malignant syndrome.
Topics: Alzheimer Disease; Amantadine; Basal Ganglia Diseases; Bromocriptine; Dantrolene; Humans; Male; Midd | 1985 |
[Syndrome involving the extrapyramidal motor systems and their drug treatment].
Topics: Amantadine; Antiparkinson Agents; Basal Ganglia Diseases; Dihydroxyphenylalanine; gamma-Aminobutyric | 1974 |
Effect of amantadine (Viregyt-K) on extrapyramidal symptoms of parkinsonian patients.
Topics: Adult; Aged; Amantadine; Basal Ganglia Diseases; Drug Administration Schedule; Extrapyramidal Tracts | 1974 |
Amantadine in extrapyramidal syndromes induced by neuroleptic drugs.
Topics: Aged; Amantadine; Basal Ganglia Diseases; Female; Humans; Male; Middle Aged; Movement Disorders; Tra | 1973 |